# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- SEC Filing
Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of...
Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced the dosing of t...
RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price tar...
Truist Securities analyst Srikripa Devarakonda maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and maintains $25 pr...
Wedbush analyst Laura Chico reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $26 price target.
"We are pleased by the promising and consistent functional results observed over two years of treatment with sevasemten, to...